EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSSBOG00000026209
Gene Symbol: ATP1A2
2 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSSBOG00000026931
Gene Symbol: ATP1A3
2 Cross references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSSBOG00000032878
Gene Symbol: ATP1B1
2 Cross references
295 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSSBOG00000024391
Gene Symbol: ATP1B2
2 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSSBOG00000025166
Gene Symbol: ATP1B3
2 Cross references
298 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atr Serine/threonine Kinase

Ensembl ID : ENSSBOG00000031886
Gene Symbol: ATR
2 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSSBOG00000025547
Gene Symbol: AXL
2 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSBOG00000028284
Gene Symbol: BRAF
2 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Apoptosis Regulator

Ensembl ID : ENSSBOG00000031435
Gene Symbol: BCL2
2 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Like 1

Ensembl ID : ENSSBOG00000034336
Gene Symbol: BCL2L1
2 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Related Protein A1

Ensembl ID : ENSSBOG00000026843
Gene Symbol: BCL2A1
2 Cross references
114 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSSBOG00000027697
Gene Symbol: BCR
2 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).